Stock comparison
Eli Lilly
Royalty Pharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | RPRX | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 66C | LLY |
| Benjamin Graham | 86A | 84A | LLY |
| Philip Fisher | 86A | 65C | LLY |
| Peter Lynch | 74B | 60C | LLY |
| Joel Greenblatt | 78C | 40D | LLY |
| Charlie Munger | 85A | 68D | LLY |
| Terry Smith | 77C | 58D | LLY |
Side-by-side metrics
| Metric | LLY | RPRX |
|---|---|---|
| Market cap | $1T | $23.44B |
| P/E (TTM) | 36.6x | 27.6x |
| EV/EBIT | 34.1x | 19.9x |
| ROIC (TTM) | 32.06% | 8.43% |
| Gross margin | 83.51% | 99.95% |
| Net margin | 34.98% | 33.91% |
| Revenue CAGR 5y | 23.17% | 0.96% |
| EPS CAGR 5y | 40.81% | 11.83% |
| Debt / Equity | 1.4x | 1.3x |
| Dividend yield | 0.62% | 1.72% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- Market cap$1Tvs $23.44B+98%
- Revenue CAGR 5y23.17%vs 0.96%+96%
- ROIC (TTM)32.06%vs 8.43%+74%
- EPS CAGR 5y40.81%vs 11.83%+71%
RPRX leads on
- Dividend yield1.72%vs 0.62%+64%
- EV/EBIT19.9xvs 34.1x+42%
- P/E (TTM)27.6xvs 36.6x+25%
- Gross margin99.95%vs 83.51%+16%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.